Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies) research hub

A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(waveLINE-004)

This study is testing a new medicine, Zilovertamab vedotin, for people with a type of blood cancer called Diffuse Large B-Cell Lymphoma. It's for patients whose cancer has come back or didn't respond to previous treatments. The main goal is to see how many people's cancer shrinks or disappears with this new drug.